Bioxyne Limited ( (AU:BXN) ) just unveiled an announcement.
Bioxyne Limited has requested a trading halt on its securities as it undertakes a bookbuild related to a capital raising effort. This move is aimed at ensuring an orderly market and will last until the company releases an announcement or until the start of normal trading on 21 March 2025. The trading halt is a strategic step in Bioxyne’s capital management, potentially impacting its financial positioning and stakeholder interests.
More about Bioxyne Limited
Bioxyne Limited operates in the biotechnology industry, focusing on the development and commercialization of health and wellness products. The company is known for its probiotic and immune health products, targeting both domestic and international markets.
Average Trading Volume: 3,430,698
Technical Sentiment Consensus Rating: Sell
Current Market Cap: A$55.33M
Learn more about BXN stock on TipRanks’ Stock Analysis page.